Roche posts in­ter­im OS da­ta from PhI­II TIG­IT tri­al af­ter leak — and an­a­lysts say it bodes well for fi­nal read­out

Roche has post­ed a snap­shot from a close­ly-watched Phase III tri­al of its TIG­IT an­ti­body af­ter an “in­ad­ver­tent dis­clo­sure.” Al­though the over­all sur­vival da­ta are …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER